Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q3

4583.TEDINET S100PLJL
Period2022-01-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥434m2022-01-01 → 2022-09-30StandaloneNet sales
Revenue¥713m2021-01-01 → 2021-12-31StandaloneNet sales (5-year summary)
Revenue¥542m2021-01-01 → 2021-09-30StandaloneNet sales
Operating income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOperating income
Operating income−¥851m2021-01-01 → 2021-09-30StandaloneOperating income
Ordinary income−¥1.0bn2022-01-01 → 2022-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-01-01 → 2021-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥843m2021-01-01 → 2021-09-30StandaloneOrdinary income
Profit before tax−¥1.0bn2022-01-01 → 2022-09-30StandaloneIncome before income taxes
Profit before tax−¥830m2021-01-01 → 2021-09-30StandaloneIncome before income taxes
Net income−¥1.0bn2022-01-01 → 2022-09-30StandaloneProfit loss
Net income−¥1.5bn2021-01-01 → 2021-12-31StandaloneNet income loss (5-year summary)
Net income−¥843m2021-01-01 → 2021-09-30StandaloneProfit loss
Total assets¥2.1bnat 2022-09-30StandaloneAssets
Total assets¥2.3bnat 2021-12-31StandaloneAssets
Total assets¥3.0bnat 2021-09-30StandaloneTotal assets (5-year summary)
Total liabilities¥431mat 2022-09-30StandaloneLiabilities
Total liabilities¥446mat 2021-12-31StandaloneLiabilities
Net assets / equity¥1.7bnat 2022-09-30StandaloneNet assets
Net assets / equity¥1.9bnat 2021-12-31StandaloneNet assets
Net assets / equity¥2.4bnat 2021-09-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.6bnat 2022-09-30StandaloneCash and deposits
Cash and deposits¥1.8bnat 2021-12-31StandaloneCash and deposits
EPS (basic)¥-23.872022-01-01 → 2022-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-5.82022-07-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-36.742021-01-01 → 2021-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-20.942021-01-01 → 2021-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-10.772021-07-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
Equity ratio78.4%at 2022-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio79.4%at 2021-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.6%at 2021-09-30StandaloneEquity to asset ratio (5-year summary)
Shares issued45,979,100at 2022-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued40,781,500at 2021-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued40,305,500at 2021-09-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥358m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-09-30−¥916m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-09-30¥434m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥434m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥681m
Reconciling Itemsreconcilingsegment profit2021-01-01 → 2021-09-30−¥328m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentrevenue2021-01-01 → 2021-09-30¥103m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentrevenue external2021-01-01 → 2021-09-30¥103m
jpcrp040300-q3r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2021-01-01 → 2021-09-30−¥757m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue2021-01-01 → 2021-09-30¥439m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentrevenue external2021-01-01 → 2021-09-30¥439m
jpcrp040300-q3r_E26096-000Drug Discovery Supportreportable segmentsegment profit2021-01-01 → 2021-09-30¥235m
Total Of Reportable Segments And Otherssegment totalrevenue2021-01-01 → 2021-09-30¥542m
Total Of Reportable Segments And Otherssegment totalrevenue external2021-01-01 → 2021-09-30¥542m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-01-01 → 2021-09-30−¥523m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 325
ItemContextValueUnit
Cost of salesCurrentYTDDuration_NonConsolidatedMember198703000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember337792000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember234990000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember860295000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember916417000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember328241000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember357902000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember1188536000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember1274320000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-850744000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-1039329000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember27000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember19000JPY
Foreign exchange gains noiPrior1YTDDuration_NonConsolidatedMember6955000JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember－JPY
Subsidy income noiPrior1YTDDuration_NonConsolidatedMember1769000JPY
Subsidy income noiCurrentYTDDuration_NonConsolidatedMember16000000JPY
Other noiPrior1YTDDuration_NonConsolidatedMember565000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember210000JPY
Non operating incomePrior1YTDDuration_NonConsolidatedMember9318000JPY
Non operating incomeCurrentYTDDuration_NonConsolidatedMember16230000JPY
Interest expenses noePrior1YTDDuration_NonConsolidatedMember973000JPY
Interest expenses noeCurrentYTDDuration_NonConsolidatedMember980000JPY
Stock issuance cost noePrior1YTDDuration_NonConsolidatedMember616000JPY
Stock issuance cost noeCurrentYTDDuration_NonConsolidatedMember2393000JPY
Foreign exchange losses noePrior1YTDDuration_NonConsolidatedMember－JPY
Foreign exchange losses noeCurrentYTDDuration_NonConsolidatedMember3020000JPY
Other noePrior1YTDDuration_NonConsolidatedMember0JPY
Other noeCurrentYTDDuration_NonConsolidatedMember286000JPY
Non operating expensesPrior1YTDDuration_NonConsolidatedMember1589000JPY
Non operating expensesCurrentYTDDuration_NonConsolidatedMember6680000JPY
Ordinary incomePrior1YTDDuration_NonConsolidatedMember-843016000JPY
Ordinary incomeCurrentYTDDuration_NonConsolidatedMember-1029779000JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration_NonConsolidatedMember12911000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration_NonConsolidatedMember5977000JPY
Extraordinary incomePrior1YTDDuration_NonConsolidatedMember12911000JPY
Extraordinary incomeCurrentYTDDuration_NonConsolidatedMember5977000JPY
Income before income taxesPrior1YTDDuration_NonConsolidatedMember-830104000JPY
Income before income taxesCurrentYTDDuration_NonConsolidatedMember-1023801000JPY
Income taxes currentPrior1YTDDuration_NonConsolidatedMember12684000JPY
Income taxes currentCurrentYTDDuration_NonConsolidatedMember3757000JPY
Income taxesPrior1YTDDuration_NonConsolidatedMember12684000JPY
Income taxesCurrentYTDDuration_NonConsolidatedMember3757000JPY
Profit lossPrior1YTDDuration_NonConsolidatedMember-842789000JPY
Profit lossCurrentYTDDuration_NonConsolidatedMember-1027559000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoveryAndDevelopmentReportableSegmentsMember103013000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_jpcrp040300-q3r_E26096-000DrugDiscoverySupportReportableSegmentsMember438676000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_TotalOfReportableSegmentsAndOthersMember541690000JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration_NonConsolidatedMember541690000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2021-12-31pass
balance sheet identitynon_consolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · revenuenon_consolidated 2021-01-01/2021-09-30pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-09-30pass
statement vs summary · total assetsnon_consolidated 2021-12-31pass
statement vs summary · total assetsnon_consolidated 2022-09-30pass